Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
Giuseppe Coppolino, Christian Leporini, Laura Rivoli, et al.
Pharmacological Research (2017) Vol. 129, pp. 274-294
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Cardiovascular Effects of New Oral Glucose-Lowering Agents
André Scheen
Circulation Research (2018) Vol. 122, Iss. 10, pp. 1439-1459
Open Access | Times Cited: 252
Accelerated Kidney Aging in Diabetes Mellitus
Jing Guo, Hui Juan Zheng, Wenting Zhang, et al.
Oxidative Medicine and Cellular Longevity (2020) Vol. 2020, pp. 1-24
Open Access | Times Cited: 75
Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia
Guido Gembillo, Ylenia Ingrasciotta, Salvatore Crisafulli, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4824-4824
Open Access | Times Cited: 61
Chronic Kidney Disease and Cognitive Impairment: The Kidney-Brain Axis
Zuoquan Xie, Siyu Tong, Xingkun Chu, et al.
Kidney Diseases (2022) Vol. 8, Iss. 4, pp. 275-285
Open Access | Times Cited: 45
New insights in the treatment of DKD: recent advances and future prospects
Meimei Zhao, Yongtong Cao, Liang Ma
BMC Nephrology (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
MicroRNA: A new generation therapeutic target in diabetic nephropathy
Saikat Dewanjee, Niloy Bhattacharjee
Biochemical Pharmacology (2018) Vol. 155, pp. 32-47
Closed Access | Times Cited: 82
Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale
Michele Provenzano, Giuseppe Coppolino, Luca De Nicola, et al.
Frontiers in Cell and Developmental Biology (2019) Vol. 7
Open Access | Times Cited: 75
SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
Carlo Garofalo, Silvio Borrelli, Maria V. Liberti, et al.
Medicina (2019) Vol. 55, Iss. 6, pp. 268-268
Open Access | Times Cited: 74
Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets
Carla Zoja, Christodoulos Xinaris, Daniela Macconi
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 62
More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling
Shreyasi Gupta, Utpal Sen
Pharmacological Research (2019) Vol. 147, pp. 104391-104391
Open Access | Times Cited: 55
Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
André Scheen
Diabetes & Metabolism (2018) Vol. 45, Iss. 2, pp. 110-121
Closed Access | Times Cited: 49
Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58
Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 1, pp. 29-38
Open Access | Times Cited: 42
Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
Rodrigo Daza-Arnedo, Jorge-Eduardo Rico-Fontalvo, Nehomar Pájaro-Galvis, et al.
Kidney Medicine (2021) Vol. 3, Iss. 6, pp. 1065-1073
Open Access | Times Cited: 36
Renoprotective Effects of DPP-4 Inhibitors
Daiji Kawanami, Yuichi Takashi, Hiroyuki Takahashi, et al.
Antioxidants (2021) Vol. 10, Iss. 2, pp. 246-246
Open Access | Times Cited: 30
Microbial dipeptidyl peptidases of the S9B family as host-microbe isozymes
Mashael R. Aljumaah, Jeffrey Roach, Yunan Hu, et al.
Science Advances (2025) Vol. 11, Iss. 14
Closed Access
Cell cycle disorders in podocytes: an emerging and increasingly recognized phenomenon
Chaojie Zhang, Jia Guo
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
Annayya R. Aroor, Camila Manrique‐Acevedo, Vincent G. DeMarco
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 32
Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension
Donato Cappetta, Loreta Pia Ciuffreda, Anna Cozzolino, et al.
Oxidative Medicine and Cellular Longevity (2019) Vol. 2019, pp. 1-13
Open Access | Times Cited: 23
Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases
Ramona Nicotera, Alessandro Casarella, Elisa Longhitano, et al.
Pharmacological Research (2020) Vol. 159, pp. 105019-105019
Closed Access | Times Cited: 21
Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment
Maria Chiara Pelle, Michele Provenzano, Isabella Zaffina, et al.
Life (2021) Vol. 12, Iss. 1, pp. 29-29
Open Access | Times Cited: 19
A Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney Disease
Chongbin Liu, Ming Yang, Li Li, et al.
Frontiers in Physiology (2022) Vol. 13
Open Access | Times Cited: 13
Dipeptidyl peptidase-4 inhibitor-related renal disease
Atsuhiko Suenaga, Naoki Sawa, Yuki Oba, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 10, pp. 108590-108590
Open Access | Times Cited: 7
Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium‐glucose co‐transporter‐2 inhibitors with those receiving dipeptidyl peptidase‐4 inhibitors, using a supervised machine‐learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database
Fang Liz Zhou, Hirotaka Watada, Yuki Tajima, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 8, pp. 1925-1934
Open Access | Times Cited: 22
Effect of Antidiabetic Drugs on Bone Health in Patients with Normal Renal Function and in Chronic Kidney Disease (CKD): Insight into Clinical Challenges in the Treatment of Type 2 Diabetes
Cristiana Cipriani, Gabriella Lauriero, Giovanni Tripepi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 23, pp. 7260-7260
Open Access | Times Cited: 6
Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease
Hugh Davis, Vanessa Jones Briscoe, Sofio Dumbadze, et al.
Expert Opinion on Investigational Drugs (2019) Vol. 28, Iss. 4, pp. 377-388
Closed Access | Times Cited: 16
Page 1 - Next Page

Scroll to top